United States Biotech Latest News

Secure, on-premises AI infrastructure, recurring revenue model, and entry into a $167B+ R&D ecosystem position $KALA at the forefront of the agentic AI healthcare revolution

NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP Has a One-Day Depression Treatment, AI Monitoring Breakthrough, and Potential 2026 Drug Approval Put $NRXP in a Category of Its Own

Philanthropic venture fund supports next generation of startups to expand opportunity and economic growth for future generations

Accelerating scalable AI infrastructure, secures up to $9.75M financing, and advances FDA-registered diagnostic technology alongside next-generation generative AI platforms $ALBT

87% Clinical Response From Non-Invasive Neuroplastic Therapy Positions $NRXP at the Forefront of Next-Generation Mental Health Treatment. NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)

TAEUS® Technology Delivers MRI-Level Liver Fat Measurement at the Point of Care for Disease Affecting 30% of Adults Worldwide: $NDRA

KALA BIO, Inc. (N A S D A Q: KALA) $KALA Targets Massive AI Opportunity in Biotech with Secure On-Premises Infrastructure Platform

Green Seal-Certified. Hospital-Grade Disinfection Meets Explosive Omni-Channel Growth Strategy Including pet-care, and biosafety sectors.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP: FDA Alignment, 70,000-Patient Real-World Data, and a Debt-Free Balance Sheet Position NRXP for Transformational 2026 Catalysts

Biobase, a healthcare data infrastructure company pioneering the first agentic operating system for clinical data, received a strategic investment from BJC Health that will position BJC as a center of excellence for deploying next-generation AI solutions.

Bridging the orbital care gap: As NASA reassesses ISS medical protocols, Diopter Labs reveals a shelf-stable "clinic-in-a-lens" built to stop space-flight emergencies before they require evacuation.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP has Entered into a Joint Offering with neurocare Group for Neuroplastic Therapy Targeting Depression, PTSD and Other Mental Health Afflictions

Secure, on-premises AI infrastructure, recurring revenue model, and entry into a $167B+ R&D ecosystem position $KALA at the forefront of the agentic AI healthcare revolution

NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP Has a One-Day Depression Treatment, AI Monitoring Breakthrough, and Potential 2026 Drug Approval Put $NRXP in a Category of Its Own

Philanthropic venture fund supports next generation of startups to expand opportunity and economic growth for future generations

Accelerating scalable AI infrastructure, secures up to $9.75M financing, and advances FDA-registered diagnostic technology alongside next-generation generative AI platforms $ALBT

87% Clinical Response From Non-Invasive Neuroplastic Therapy Positions $NRXP at the Forefront of Next-Generation Mental Health Treatment. NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)

TAEUS® Technology Delivers MRI-Level Liver Fat Measurement at the Point of Care for Disease Affecting 30% of Adults Worldwide: $NDRA

KALA BIO, Inc. (N A S D A Q: KALA) $KALA Targets Massive AI Opportunity in Biotech with Secure On-Premises Infrastructure Platform

Green Seal-Certified. Hospital-Grade Disinfection Meets Explosive Omni-Channel Growth Strategy Including pet-care, and biosafety sectors.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP: FDA Alignment, 70,000-Patient Real-World Data, and a Debt-Free Balance Sheet Position NRXP for Transformational 2026 Catalysts

Company focuses on compliant, research-use-only biotech compounds for laboratory clients

Biobase, a healthcare data infrastructure company pioneering the first agentic operating system for clinical data, received a strategic investment from BJC Health that will position BJC as a center of excellence for deploying next-generation AI solutions.

Bridging the orbital care gap: As NASA reassesses ISS medical protocols, Diopter Labs reveals a shelf-stable "clinic-in-a-lens" built to stop space-flight emergencies before they require evacuation.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP has Entered into a Joint Offering with neurocare Group for Neuroplastic Therapy Targeting Depression, PTSD and Other Mental Health Afflictions

BullFrog AI Holdings, Inc. (N A S D A Q: BFRG) $BFRG Published Whitepaper Titled "AI in Bioinformatics: Turning Complex Data into Actionable Insights with BullFrog Data Networks®"

VSee Health, Inc. (N A S D A Q: VSEE) $VSEE Reported Q3 Revenues Reach $3.98 Million, Up 19% Year-Over-Year with Clients Including NASA, U.S. Department of Health and Human Services, McKesson, DaVita and The Nation of Qatar

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) NRXP Also Reports Its Superior Preservative-Free IV Ketamine Now Submitted for FDA Abbreviated New Drug Application

OKAVA Pharmaceuticals is a clinical-stage company developing medicines to enable dogs and cats to live longer, healthier lives.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP; $750 Million Market for Suicidal Depression Market Awaits

Learn how surface plasmon resonance service provides accurate kinetic data for drug discovery and molecular interaction studies.

$NRXP Has Manufactured Multiple Commercial Lots of NRX-100 and KETAFREE™ with a Shelf Life of Three Years.

Analyst D. Boral Targets NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP at $34 Per Share — Pioneering Breakthroughs in Treatment-Resistant Depression and Chronic Pain

H.C. Wainwright Initiates Coverage with $34 Price Target, Citing Paradigm Shift in Depression Treatment. NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP

Founder of 360Disruption leads cross-border FDI and healthtech ventures aligned with UAE Vision 2031 and GCC Vision frameworks.

As therapeutic antibodies continue to reshape modern medicine, one challenge remains at the core of successful drug development — minimizing immune reactions while preserving antibody function.

Program to Advance Next-Generation Legumain-Cleavable ADC Platform for Advanced Cancers

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Refiles Abbreviated New Drug Application; $40 Price Target in New H. C. Wainright Research Report

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Suitability Petition is required for shift from multidose packaging of ketamine to single-patient dose preservative free ketamine

WorldUpstart proudly announces the launch of its Fall 2025 U.S. Market Gateway Accelerator, featuring a dynamic cohort of international Life Science and MedTech companies.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Continues Expansion with Completion of Dura Medical Acquisition in Network of Interventional Psychiatry Clinics

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Sees 10-Fold Market Expansion to 13 Million Americans for Bipolar Depression Alone.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Has $7.8 Million for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD